Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects. New basic science findings from a University of Iowa study suggest a way that treatments could potentially be refined so that they work better and target only key heart-related mechanisms. Continue Reading
The C.S. Mott Center for Human Growth and Development, Department of Obstetrics and Gynecology, at the Wayne State University School of Medicine, in collaboration with the Center for Molecular Medicine and Genetics, the Karmanos Cancer Institute and the Institute for Environmental Health Sciences, installed a Genomatix Mining Station and a Genomatix Genome Analyzer last year at their labs in Detroit, MI in order to support the analysis of Next Generation Sequencing (NGS) data. Continue Reading
Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump unwanted or toxic substances away from vulnerable tissues, has announced positive results of a Phase 1a trial for its lead compound, LIM-0705, which has completed its first in man study. Continue Reading
BioTime, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2009 and provided an update on recent corporate developments. Continue Reading
New preliminary data from a pilot study in the Netherlands indicates that imaging tools may help address the most challenging clinical dilemma of prostate cancer care as identified by the hearing of the House Oversight and Government Reform Committee and its expert witnesses last week: to treat or not treat, AdMeTech Foundation’s President and CEO Dr. Faina Shtern said today. Continue Reading
The interaction of a ligand (Neurotrophine-3) and its dependence receptor (TrkC) constitutes a novel mechanism for tumor control in pediatric cancers such as neuroblastoma, and may also be important to the inhibition of other cancers such as breast cancer. Continue Reading
Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule. Continue Reading
Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels. Continue Reading
Taro Pharmaceutical Industries Ltd. today reported that it received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Fluorouracil Topical Cream USP, 5%. Continue Reading
Prostate-specific dietary supplements should not be taken during radiation therapy treatments because they have been shown to increase the radiosensitivity of normal prostate cell lines, leading to normal tissue complications, according to a study in the March issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology. Continue Reading
